《大行報告》富瑞下調康龍化成(03759.HK)目標價至200元 評級「買入」
富瑞發表報告,將康龍化成(03759.HK)2022年至2024年的銷售額預測上調3%-7%,但將同期的每股盈利下調9%-13%,將康龍化成H股目標價從224元下調至200元,評級「買入」。
該行表示,仍然看好康龍化成,並相信它有足夠的空間進一步擴展到生物製劑、CGT、臨床CRO和CMO,這可能會擴展其具有交叉銷售協同效應的每個分子和每個客戶的收入流。
富瑞認為,對於進入新業務線的參與者來說,去槓桿是不可避免的,預計隨著新業務線的成熟,盈利增長將正常化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.